The Role of Osteoarthritis Severity, BMI and Age on Clinical Efficacy of Bone Marrow Aspirate Concentrate in the Treatment of Knee Osteoarthritis

Rasovic, Predrag; Dulić, Oliver; Lalić, Ivica; Matijević, Radmila; Janjić, Nataša; Tošić, Milan; Aleksandric, Dejan; Abazović, Džihan; Miškulin, Mladen; Matijevic, Suzan; Kovacevic, Luka

doi:10.2217/rme-2023-0042

Cited by 5 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was confirmed in a study of 111 participants by Rasovic, who reported, that participants' age and BMI did not influence the clinical outcome, but there was an influence of OA severity, especially among older patients. His study shows that BMAC therapy is effective and he states, that younger patients with milder OA changes could be better candidates for long-lasting and more efficient BMAC therapy 39 www.nature.com/scientificreports/ with grade I to grade IV degenerative arthritis of the knee and confirmed this findings, that a BMAC injection significantly improved both knee pain and functions in the patients with degenerative arthritis of knee. Also, the injection would be more effective in early to moderate phases 40 .…”

Section: Discussionmentioning

confidence: 74%

Intra-articular injection of bone marrow aspirate concentrate (mesenchymal stem cells) in KL grade III and IV knee osteoarthritis: 4 year results of 37 knees

Pabinger,

Lothaller,

Kobinia

2024

Sci Rep

View full text Add to dashboard Cite

Cell based therapies are increasingly used and results of bone marrow aspirate concentrate (BMAC) show encouraging short- to middle term results, superior to hyaluronic acid and platelet rich plasma (PRP). Most studies describe patients with mild to moderate arthritis and results of patients with KL III and IV osteoarthritis of the knee are limited to short term evaluations. Hence, the aim of this prospective study was to investigate the mid-term outcome of BMAC injections in patients with severe osteoarthritis of the knee. The BMAC was retrieved from the iliac crest as previously published with the “reorientation technique” from the iliac crest in supine position in analgosedation and injected into the patients’ osteoarthritic knees. Patients were followed-up for 4 years. WOMAC, IKDC, SF 36 and walking distance were measured in a total of 37 participants. There was an improvement of IKDC and WOMAC from the first year onwards and a significant improvement beginning from year 2 up to the mid-term follow-up: IKDC increased significantly from 56 ± 12 (range 34–81) to 73 ± 13 (range 45–100), p < 0.001. WOMAC decreased significantly from 40 ± 23 (range 6–96) to 18 ± 18 (range 0–67), p < 0.001. 35 of 37 knees improved regarding IKDC and WOMAC score from the first to the last follow-up. Not a single protheses had to be implanted. Elaborate statistical analysis was done to exclude covariates and confounders (age, time, BMI,…). In summary, this is the first study on BMAC injections into 37 osteoarthritic knees with a 4-year follow up showing significant improvements in IKDC and WOMAC scores, and with a 95% success rate and significant improvement in walking distance.Clinical relevance Describes the 4-year outcome of BMAC injections for knees with severe osteoarthritis.

show abstract

Section: Discussionmentioning

confidence: 74%

Intra-articular injection of bone marrow aspirate concentrate (mesenchymal stem cells) in KL grade III and IV knee osteoarthritis: 4 year results of 37 knees

Pabinger,

Lothaller,

Kobinia

2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…His study shows that BMAC therapy is effective and he states, that younger patients with milder OA changes could be better candidates for long-lasting and more e cient BMAC therapy. 39 Kim assessed the outcome of BMAC injection in patients with grade I to grade IV degenerative arthritis of the knee and con rmed this ndings, that a BMAC injection signi cantly improved both knee pain and functions in the patients with degenerative arthritis of knee. Also, the injection would be more effective in early to moderate phases.…”

Section: Discussionmentioning

confidence: 83%

Intra-articular injection of bone marrow aspirate concentrate in end stage knee osteoarthritis: 4 year results of 37 knees

Pabinger,

Kobinia,

Lothaller

2023

Preprint

View full text Add to dashboard Cite

Purpose: Cell based therapies are increasingly used and results of bone marrow aspirate concentrate (BMAC) show encouraging short- to middle term results, superior to hyaluronic acid and platelet rich plasma (PRP). Most studies describe patients with mild to moderate arthritis and short term results of patients with severe osteoarthritis of the knee. Hence, the aim of this prospective study was to investigate the mid-term outcome of BMAC injections in patients with severe osteoarthritis of the knee. Methods: The BMAC was retrieved from the iliac crest as previously published with the “reorientation technique” from the iliac crest in prone position in sedoanalgesia and injected into the patients’ osteoarthritic knees. Patients were followed-up for 4 years. WOMAC, IKDC, SF 36 and walking distance were measured in a total of 37 participants. Results There was an improvement of IKDC and WOMAC from the first year onwards and a significant improvement beginning from year 2 up to the mid-term follow-up: IKDC increased significantly from 56±12 (range 34-81) to 73±13 (range 45-100), p<.001. WOMAC decreased significantly from 40±23 (range 6-96) to 18 ±18 (range 0-67), p<.001. 35 of 37 knees improved regarding IKDC and WOMAC score from the first to the last follow-up. Not a single protheses had to be implanted. Elaborate statistical analysis was done to exclude covariates and confounders (age, time, BMI,…) . Conclusion In summary, this is the first study on BMAC injections into 37 osteoarthritic knees with a 4- year follow up showing significant improvements in IKDC and WOMAC scores, and with a 95% success rate and significant improvement in walking distance. Level of Evidence: Level I

show abstract

“…The results showed that BMAC injection effectively improved pain in knee OA patients with short-to mid-term follow-up 15 . A recent study by Rascovic et al (2023) involving 111 patients also showed that BMAC therapy is effective, especially for younger patients with milder OA 16 . The combination of intra-articular and subchondral BMAC injection can provide clinical and imaging benefits for up to 24 months in patients with knee OA 17 .…”

Section: Bone Marrow Aspirate Concentratesmentioning

confidence: 93%

Hyaluronic acid, platelet-rich plasma, bone marrow aspirate concentrate, the stromal vascular fraction, or mesenchymal stem cells: which is the best candidate for treating knee osteoarthritis?

Phuong,

Ngoc,

Phuc

2023

Biomed. Res. Ther.

View full text Add to dashboard Cite

Regenerative medicine-based therapies are considered promising for some chronic diseases, such as osteoarthritis (OA). Because OA is the most common disease in many countries, significant efforts have long been made to develop effective treatments. Current therapies for OA include hyaluronic acid, platelet-rich plasma, bone marrow aspirate concentrates, the stromal vascular fraction from adipose tissue, bone marrow-derived mesenchymal stem cells, and adipose tissue-derived mesenchymal stem cells. Clinical trials testing these agents for OA treatment have been performed for over 10 years. In this review, we summarize and compare the effects of these agents for treating knee OA based on recent meta-analyses.

show abstract

The Role of Osteoarthritis Severity, BMI and Age on Clinical Efficacy of Bone Marrow Aspirate Concentrate in the Treatment of Knee Osteoarthritis

Cited by 5 publications

References 31 publications

Intra-articular injection of bone marrow aspirate concentrate (mesenchymal stem cells) in KL grade III and IV knee osteoarthritis: 4 year results of 37 knees

Intra-articular injection of bone marrow aspirate concentrate (mesenchymal stem cells) in KL grade III and IV knee osteoarthritis: 4 year results of 37 knees

Intra-articular injection of bone marrow aspirate concentrate in end stage knee osteoarthritis: 4 year results of 37 knees

Hyaluronic acid, platelet-rich plasma, bone marrow aspirate concentrate, the stromal vascular fraction, or mesenchymal stem cells: which is the best candidate for treating knee osteoarthritis?

Contact Info

Product

Resources

About